After Cowen & Co. and B.Riley FBR gave Apellis Pharmaceuticals Inc (NASDAQ: APLS) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Elemer Piros reiterated a Buy rating on Apellis Pharmaceuticals Inc yesterday and set a price target of $53. The company’s shares closed yesterday at $17.45.
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -8.3% and a 39.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Currently, the analyst consensus on Apellis Pharmaceuticals Inc is a Strong Buy with an average price target of $40, implying a 129.2% upside from current levels. In a report issued on July 30, B.Riley FBR also upgraded the stock to Buy with a $27 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32 and a one-year low of $12.45. Currently, Apellis Pharmaceuticals Inc has an average volume of 437.6K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product.
